LipoVation
Preclinical biotechnology company developing lipid- and nanoparticle-based delivery systems for systemic therapeutics and for vaccine antigen delivery. Pipeline includes reformulation of topical antibiotics for systemic use, lipid-based protein antigen vaccine platforms, and tumor-targeted nanoparticle adjuvants. Activities span preclinical studies through IND-enabling and early clinical development. The company completed a strategic acquisition to expand liposome and nanoparticle capabilities.
Industries
Nr. of Employees
small (1-50)
Products
Injectable liposomal reformulation of mupirocin
Liposomal injectable formulation of mupirocin intended to enable systemic administration and enhanced delivery to inflamed or infected tissues.
Nanoparticle-encapsulated angiotensin receptor blocker for tumor targeting
Nanoparticle formulation of an angiotensin receptor blocker intended as a tumor-targeted adjuvant to immunotherapies and chemotherapies to modulate the tumor microenvironment.
Lipid-based protein antigen vaccine platform
Lipid assembly platform for protein antigen delivery intended to improve antigen presentation and immune response durability for emerging infectious disease targets.
Injectable liposomal reformulation of mupirocin
Liposomal injectable formulation of mupirocin intended to enable systemic administration and enhanced delivery to inflamed or infected tissues.
Nanoparticle-encapsulated angiotensin receptor blocker for tumor targeting
Nanoparticle formulation of an angiotensin receptor blocker intended as a tumor-targeted adjuvant to immunotherapies and chemotherapies to modulate the tumor microenvironment.
Lipid-based protein antigen vaccine platform
Lipid assembly platform for protein antigen delivery intended to improve antigen presentation and immune response durability for emerging infectious disease targets.
Services
Preclinical development of lipid- and nanoparticle-based therapeutics
Internal R&D advancing liposomal reformulations, nanoparticle constructs, and lipid-based vaccine candidates through preclinical efficacy testing and IND-enabling activities.
CMC planning and GMP clinical-batch production management
CMC strategy development and coordination with contract development and manufacturing organizations to produce GMP clinical batches for regulatory submissions and first-in-human studies.
Preclinical development of lipid- and nanoparticle-based therapeutics
Internal R&D advancing liposomal reformulations, nanoparticle constructs, and lipid-based vaccine candidates through preclinical efficacy testing and IND-enabling activities.
CMC planning and GMP clinical-batch production management
CMC strategy development and coordination with contract development and manufacturing organizations to produce GMP clinical batches for regulatory submissions and first-in-human studies.
Expertise Areas
- Liposomal and nanoparticle drug formulation
- Drug-loading and controlled-release optimization for lipid carriers
- Lipid-based vaccine antigen delivery
- Preclinical efficacy and microbiological susceptibility testing
Key Technologies
- Liposomal drug delivery
- Nanoparticle drug delivery
- Remote drug-loading methods
- Controlled-release lipid systems